News and Trends 2 May 2023
Cabaletta Bio’s lupus drug cleared for trial
Cabaletta Bio, Inc., a U.S. clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the U.S. Food…